BCAL Diagnostics (ASX:BDX) Marketable Securities : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. BCAL Diagnostics's Marketable Securities for the quarter that ended in Dec. 2023 was A$0.00 Mil.

BCAL Diagnostics's annual Marketable Securities increased from . 20 (A$0.00 Mil) to Jun. 2022 (A$4.00 Mil) but then declined from Jun. 2022 (A$4.00 Mil) to Jun. 2023 (A$0.00 Mil).

BCAL Diagnostics Marketable Securities Historical Data

The historical data trend for BCAL Diagnostics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Marketable Securities Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

Marketable Securities

4.00

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Marketable Securities	Get a 7-Day Free Trial			7.00	4.00	-	-	-

BCAL Diagnostics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

BCAL Diagnostics (ASX:BDX) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

BCAL Diagnostics Marketable Securities Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics (ASX:BDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.